TCF23 Regulates Immune Response and Cancer Development (G150921)

Target Name: TCF23

NCBI ID: G150921

TCF23

TCF23 Regulates Immune Response and Cancer Development

TCF23 is a protein that is expressed in many tissues throughout the body. It is a member of the T-cell costimulatory complex, which is a protein complex that is involved in the regulation of T-cell activation and proliferation. TCF23 is a critical protein for the proper functioning of T cells, and it is potential target for new drugs.

One of the key functions of TCF23 is its role in regulating the level of surface expression of the protein PD-L1. PD-L1 is a protein that is expressed in many tissues, including immune cells, and it plays a role in promoting the immune response. TCF23 is known to interact with PD-L1 and to regulate the level of its expression. This interaction between TCF23 and PD-L1 is important for the proper functioning of the immune system, as it allows T cells to be responsive to PD-L1 and to differentiate into CD4+ and CD8+ T cells.

Another function of TCF23 is its role in regulating the level of the protein PD-L1-PD1. PD-L1-PD1 is a protein that is expressed in many tissues, including immune cells, and it plays a role in promoting the immune response. TCF23 is known to interact with PD-L1-PD1 and to regulate the level of its expression. This interaction between TCF23 and PD-L1-PD1 is important for the proper functioning of the immune system, as it allows T cells to be responsive to PD-L1-PD1 and to differentiate into CD4+ and CD8+ T cells.

TCF23 is also involved in the regulation of the immune response by promoting the production of regulatory T cells. Regulatory T cells are a type of T cell that play a critical role in the immune system by regulating the activity of other immune cells. TCF23 is known to interact with the protein PD-L1 and to promote the production of regulatory T cells. This interaction between TCF23 and PD-L1 is important for the proper functioning of the immune system, as it allows T cells to be responsive to PD-L1 and to differentiate into regulatory T cells.

In addition to its role in regulating the immune response, TCF23 is also involved in the regulation of the development and progression of cancer. TCF23 is known to interact with the protein PD-L1 and to promote the development of cancer. This interaction between TCF23 and PD-L1 is important for the proper functioning of the immune system, as it allows T cells to be responsive to PD-L1 and to promote the growth and progression of cancer.

Overall, TCF23 is a protein that is involved in the regulation of many important processes in the immune system. Its functions include regulating the level of surface expression of PD-L1, regulating the level of PD-L1-PD1, and promoting the production of regulatory T cells. TCF23 is also involved in the regulation of the immune response and in the development and progression of cancer. As a result, TCF23 is a potential drug target and a biomarker for a variety of diseases.

Protein Name: Transcription Factor 23

Functions: Inhibits E-box-mediated binding and transactivation of bHLH factors. Inhibitory effect is similar to that of ID proteins. Inhibits the formation of TCF3 and MYOD1 homodimers and heterodimers. Lacks DNA binding activity. Seems to play a role in the inhibition of myogenesis (By similarity)

The "TCF23 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about TCF23 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets